Mangalam drugs & organics Limited has filed a revised disclosure with BSE and NSE regarding the resignation of its Company Secretary & Compliance Officer, following communication from BSE about discrepancies in the earlier submission.

Regulatory Filing Details

The company submitted the revised disclosure on April 17, 2026, under reference number MDOL/CS-SE/2026-27/004, addressing the requirements of Regulation 30 of SEBI (LODR) Regulations, 2015. The filing was signed by Chairman & Managing Director Govardhan M. Dhoot and submitted to both stock exchanges.

Resignation Details

Ms. Anuradha Pandey tendered her resignation from the position of Company Secretary & Compliance Officer effective March 29, 2026. The resignation was formally submitted through a letter dated January 2, 2026, where Pandey cited her decision to pursue opportunities that align more closely with her long-term career goals and aspirations.

Administrative Oversight Acknowledged

The company explained that the resignation disclosure could not be submitted within the prescribed timeline of 7 days from the effective date due to an inadvertent administrative oversight. This resulted in the timeline for filing the mandatory disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 not being tracked appropriately.

The revised submission includes detailed documentation as required under SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Transition and Cooperation

In her resignation letter, Pandey expressed gratitude for the opportunities provided during her tenure and committed to ensuring a smooth transition of responsibilities. She offered her best cooperation during the notice period to facilitate continuity in operations and assist in training her successor.

The company has complied with SEBI circular requirements by providing detailed reasons for the resignation and acknowledging the procedural delay in filing the mandatory disclosure.

Mangalam Drugs & Organics Limited has disclosed subsequent defaults on its bank loan accounts under SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The pharmaceutical company reported overdue amounts totaling ₹1558.05 lacs across two cash credit facilities as of April 15, 2026.

Default Details and Timeline

The company's disclosure reveals defaults on cash credit facilities with two major banks, both exceeding the regulatory threshold of 30 days. The defaults began in October 2025 and have continued into April 2026.

Regulatory Compliance and Disclosure

The disclosure was made under Regulation 30, Part A of Schedule III of SEBI regulations, which mandates listed entities to report defaults on debt obligations without applying materiality guidelines. The regulation specifically covers situations where outstanding balances in revolving facilities like cash credit remain continuously in excess of sanctioned limits for more than thirty days.

Managing Director Govardhan M. Dhoot signed the regulatory filing dated April 16, 2026, addressed to both BSE Limited and National Stock Exchange of India Limited. The company's scrip code on BSE is 532637, while it trades under the symbol MANGALAM on NSE.

Management Response

The company has acknowledged the default situation and indicated efforts toward resolution. Management stated they are making arrangements to pay the overdue amounts as soon as possible. Chief Financial Officer Jeevan Dalvi also signed internal documentation confirming the default status.

Previous Disclosures

The current disclosure references a previous letter dated February 16, 2026, suggesting this is part of ongoing communication regarding the company's loan default situation. The subsequent disclosure indicates the defaults have persisted beyond the initial reporting period.

The company maintains its registered office at Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G.P.O. Mumbai, and operates as a WHO-GMP accredited pharmaceutical manufacturer with CIN L24230MH1972PLC116413.